Panel 4: Advancing Discovery to First-In-Human Clinical Trials for New Medical Products

Moderators:
- Jay Bradner, MD - President of Novartis Institutes for Biomedical Research
- Joseph Wu, MD, PhD - Director of the Stanford Cardiovascular Institute

Panelists:
- Hal Barron, MD - Chief Scientific Officer at GlaxoSmithKline
- Tejal Desai, PhD - Chair, Bioengineering and Therapeutic Sciences at UCSF
- Mathai Mammen, MD, PhD - Global Head of Research and Development at Janssen
- Peter Marks, MD, PhD - Director of Center for Biologics Evaluation and Research at FDA

• Which emerging capabilities promise to accelerate and improve the chances of success from discovery to first in human clinical trials?

• For innovative new products, how should the FDA acquire the scientific knowledge necessary to make good decisions about safety and efficacy?

• How can stakeholders play a role in supporting regulatory science outside the context of a specific product?